The role of new asthma treatments
Inhaled corticosteroid therapy remains the basis for the treatment of chronic asthma. Recent understanding of its use includes the benefits of early introduction, and of its plateaued dose-benefit effects. Additional beneficial effects on asthma control and prevention of asthma exacerbations can be...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
1998-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015315641 |
| _version_ | 1819168797634854912 |
|---|---|
| author | K.F. Chung |
| author_facet | K.F. Chung |
| author_sort | K.F. Chung |
| collection | DOAJ |
| description | Inhaled corticosteroid therapy remains the basis for the treatment of chronic asthma. Recent understanding of its use includes the benefits of early introduction, and of its plateaued dose-benefit effects. Additional beneficial effects on asthma control and prevention of asthma exacerbations can be obtained by combining middle- to high-dose inhaled corticosteroid with long-acting β-agonists and slow-release theophylline. Leukotriene inhibitors, particularly leukotriene receptor antagonists, are novel treatments that may also be combined with inhaled steroid therapy. Although current asthma treatments are very effective, a subgroup of asthma patients (difficult or therapy-resistant asthma) do not respond adequately to these treatments and need maintained oral corticosteroid therapy. New asthma treatments are particularly needed for this group. New treatments for asthma include more potent topical corticosteroids which have less potential for side-effects, inhibition of eosinophil chemotaxis and activation such as anti-IL-5, anti-eotaxin, eotaxin receptor antagonist, anti-VL-A4, anti-IgE therapy, restoring Th-1/Th-2 balance either by increasing Th-1 or reducing Th-2 T-cell activity, antiinflammatory cytokines such as IL-10, and specific inhibitors of PDE4. These treatments may be considered as either controllers, remitters (inducing remission of disease), or preventors according to their modes of action and their clinical effects. Currently, there does not appear to be any prospect of a cure for asthma. |
| first_indexed | 2024-12-22T19:09:19Z |
| format | Article |
| id | doaj.art-a94cbecac446468aa8d06e8020578f3a |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-12-22T19:09:19Z |
| publishDate | 1998-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-a94cbecac446468aa8d06e8020578f3a2022-12-21T18:15:42ZengElsevierAllergology International1323-89301998-01-0147423724610.2332/allergolint.47.237The role of new asthma treatmentsK.F. ChungInhaled corticosteroid therapy remains the basis for the treatment of chronic asthma. Recent understanding of its use includes the benefits of early introduction, and of its plateaued dose-benefit effects. Additional beneficial effects on asthma control and prevention of asthma exacerbations can be obtained by combining middle- to high-dose inhaled corticosteroid with long-acting β-agonists and slow-release theophylline. Leukotriene inhibitors, particularly leukotriene receptor antagonists, are novel treatments that may also be combined with inhaled steroid therapy. Although current asthma treatments are very effective, a subgroup of asthma patients (difficult or therapy-resistant asthma) do not respond adequately to these treatments and need maintained oral corticosteroid therapy. New asthma treatments are particularly needed for this group. New treatments for asthma include more potent topical corticosteroids which have less potential for side-effects, inhibition of eosinophil chemotaxis and activation such as anti-IL-5, anti-eotaxin, eotaxin receptor antagonist, anti-VL-A4, anti-IgE therapy, restoring Th-1/Th-2 balance either by increasing Th-1 or reducing Th-2 T-cell activity, antiinflammatory cytokines such as IL-10, and specific inhibitors of PDE4. These treatments may be considered as either controllers, remitters (inducing remission of disease), or preventors according to their modes of action and their clinical effects. Currently, there does not appear to be any prospect of a cure for asthma.http://www.sciencedirect.com/science/article/pii/S1323893015315641asthmaβ-adrenergic agonistscorticosteroidseosinophilstreatments |
| spellingShingle | K.F. Chung The role of new asthma treatments Allergology International asthma β-adrenergic agonists corticosteroids eosinophils treatments |
| title | The role of new asthma treatments |
| title_full | The role of new asthma treatments |
| title_fullStr | The role of new asthma treatments |
| title_full_unstemmed | The role of new asthma treatments |
| title_short | The role of new asthma treatments |
| title_sort | role of new asthma treatments |
| topic | asthma β-adrenergic agonists corticosteroids eosinophils treatments |
| url | http://www.sciencedirect.com/science/article/pii/S1323893015315641 |
| work_keys_str_mv | AT kfchung theroleofnewasthmatreatments AT kfchung roleofnewasthmatreatments |